New weekly shot could boost growth in babies with dwarfism
NCT ID NCT06079398
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a weekly injection called TransCon CNP in infants under 2 years old with achondroplasia, the most common form of dwarfism. The goal is to see if it safely improves growth over 52 weeks. About 72 babies will take part, with some receiving the drug and others a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Navepegritide (TransCon CNP)
What this could lead to
If successful, this could lead to a treatment that improves growth in infants with achondroplasia, potentially reducing some complications of the condition.
What could go wrong
This is an early Phase 2 trial with only 72 infants, so results may not confirm benefit. Side effects are possible, and the treatment may not work for all.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ascendis Investigational Site
RECRUITINGSaint Paul, Minnesota, 55102, United States
-
Ascendis Investigational Site
RECRUITINGHouston, Texas, 77030, United States
-
Ascendis Investigational Site
RECRUITINGMadison, Wisconsin, 53705, United States
-
Ascendis Investigational Site
RECRUITINGParkville, 3052, Australia
-
Ascendis Investigational Site
RECRUITINGLinz, 4020, Austria
-
Ascendis Investigational Site
RECRUITINGMontreal, H3T 1C5, Canada
-
Ascendis Investigational Site
RECRUITINGCopenhagen, 2100, Denmark
-
Ascendis Investigational Site
RECRUITINGHelsinki, 00029, Finland
-
Ascendis Investigational Site
RECRUITINGParis, 75743, France
-
Ascendis Investigational Site
RECRUITINGBerlin, 13353, Germany
-
Ascendis Investigational Site
RECRUITINGCologne, 50931, Germany
-
Ascendis Investigational Site
RECRUITINGDublin, D01 YC76, Ireland
-
Ascendis Investigational Site
RECRUITINGMilan, 20132, Italy
-
Ascendis Investigational Site
RECRUITINGAuckland, 1023, New Zealand
-
Ascendis Investigational Site
RECRUITINGOslo, 0372, Norway
-
Ascendis Investigational Site
RECRUITINGCoimbra, 3000-602, Portugal
-
Ascendis Investigational Site
RECRUITINGStockholm, 17176, Sweden
-
Ascendis Investigational Site
RECRUITINGLondon, SE1 7EH, United Kingdom